Epacadostat
- Generic Name
- Epacadostat
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C11H13BrFN7O4S
- CAS Number
- 1204669-58-8
- Unique Ingredient Identifier
- 71596A9R13
- Background
Epacadostat has been used in trials studying the treatment of HL, Melanoma, Glioblastoma, Mucosal Melanoma, and Ovarian Carcinoma, among others.
- Associated Conditions
- -
- Associated Therapies
- -
Phase I/II Study of Immunotherapy Combination BN-Brachyury Vaccine, M7824, N-803 and Epacadostat (QuEST1)
- First Posted Date
- 2018-04-11
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 53
- Registration Number
- NCT03493945
- Locations
- πΊπΈ
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Epacadostat, Cladribine and Cytarabine (ECC) in AML
- First Posted Date
- 2018-04-09
- Last Posted Date
- 2018-09-11
- Lead Sponsor
- Insel Gruppe AG, University Hospital Bern
- Registration Number
- NCT03491579
- Locations
- π¨π
Departement of Medical Oncology, University Hospital Berne, Berne, Switzerland
A Window of Opportunity Study to Investigate Mechanisms of Actions of Novel Therapeutic Agents in Patients With Resectable Solid Tumor Malignancies
- First Posted Date
- 2018-03-20
- Last Posted Date
- 2021-08-26
- Target Recruit Count
- 2
- Registration Number
- NCT03471286
- Locations
- πΊπΈ
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
Epacadostat and Pembrolizumab in Patients With Head and Neck Cancer That Have Failed Prior Immunotherapy
- Conditions
- Interventions
- First Posted Date
- 2018-03-13
- Last Posted Date
- 2020-01-27
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 2
- Registration Number
- NCT03463161
- Locations
- πΊπΈ
University of Chicago Medical Center, Chicago, Illinois, United States
Epacadostat, Idarubicin and Cytarabine (EIC) in AML
- Conditions
- Interventions
- First Posted Date
- 2018-02-23
- Last Posted Date
- 2018-09-11
- Lead Sponsor
- Insel Gruppe AG, University Hospital Bern
- Registration Number
- NCT03444649
- Locations
- π¨π
Departement of Medical Oncology, University Hospital Berne, Berne, Switzerland
Epacadostat and Pembrolizumab in Treating Participants With Advanced Pancreatic Cancer
- Conditions
- ATM Gene MutationDeleterious BRCA1 Gene MutationDeleterious BRCA2 Gene MutationHomologous Recombination DeficiencyPancreatic Ductal AdenocarcinomaStage II Pancreatic Cancer AJCC v8Stage IIA Pancreatic Cancer AJCC v8Stage IIB Pancreatic Cancer AJCC v8Stage III Pancreatic Cancer AJCC v8Stage IV Pancreatic Cancer AJCC v8
- Interventions
- First Posted Date
- 2018-02-14
- Last Posted Date
- 2019-05-30
- Lead Sponsor
- M.D. Anderson Cancer Center
- Registration Number
- NCT03432676
A Study of Epacadostat, an IDO1 Inhibitor, in Combination With Pembrolizumab in Patients With Metastatic and/or Locally Advanced Sarcoma
- First Posted Date
- 2018-01-29
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT03414229
- Locations
- πΊπΈ
Memorial Sloan Kettering Cancer Center, New York, New York, United States
ALCMI-005: Pembrolizumab and Epacadostat in Treating Patients With Extensive Stage Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-01-18
- Last Posted Date
- 2018-10-10
- Lead Sponsor
- City of Hope Medical Center
- Registration Number
- NCT03402880
- Locations
- πΊπΈ
City of Hope Medical Center, Duarte, California, United States
πΊπΈCity of Hope South Pasadena, South Pasadena, California, United States
πΊπΈDana-Farber Cancer Institute, Boston, Massachusetts, United States
Pembrolizumab + Epacadostat vs Pembrolizumab + Placebo in Recurrent or Progressive Metastatic Urothelial Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2017-12-15
- Last Posted Date
- 2021-11-30
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 84
- Registration Number
- NCT03374488
- Locations
- π«π·
Centre de Lutte Contre le Cancer Francois Baclesse, Caen, France
π«π·Clinique Victor Hugo, Le Mans, France
π«π·Centre Leon Berard, Lyon, France
Pembrolizumab in Combination With Epacadostat or Placebo in Cisplatin-ineligible Urothelial Carcinoma (KEYNOTE-672/ECHO-307)
- Conditions
- Interventions
- First Posted Date
- 2017-12-05
- Last Posted Date
- 2021-12-16
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 93
- Registration Number
- NCT03361865
- Locations
- πΊπΈ
University of California Irvine Medical Center, Orange, California, United States
πΊπΈYale Cancer Center, New Haven, Connecticut, United States
πΊπΈUniversity of Tennessee Medical Center Knoxville, Knoxville, Tennessee, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.